Hanwha Offers Up to $1.2 Billion for Austal US Business 
Airbus Joins Air India A320 Altitude Drop Probe 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
US Judge Dismisses Gautam Adani Criminal Charges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
PARSIPPANY, N.J., Feb. 16, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2018 RBC Capital Markets Healthcare Conference at 9:30 AM ET on Wednesday, February 21, 2018 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
